Welcure Drugs

Welcure Drugs has announced that a Singapore-based firm will acquire a 25% equity stake in the company, marking a significant step in its strategic growth trajectory. The investment is expected to strengthen Welcure Drugs’ financial position, expand its market reach, and support research and development initiatives. Analysts view this move as a vote of confidence in the company’s operational capabilities and growth potential.

Welcure Drugs Ltd. has unveiled plans for a share split alongside a bonus share issuance, marking a strategic move to improve liquidity and broaden shareholder participation. The company’s board approved a stock split and declared bonus shares to existing investors, aiming to make its shares more affordable and attractive in the secondary market. These corporate actions reflect Welcure Drugs’ commitment to optimizing capital structure while rewarding shareholders.